Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In.
On March 23, The Wall Street Journal reported that Gilead Sciences, Inc. (NASDAQ:GILD) plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. The company also intends to develop the acquired assets in collaboration with Galapagos NV. Under the deal terms, Gilead would purchase all outstanding equity of Ouro for about $1.68 billion in cash upfront, payable at closing, along with up to $500 million in contingent milestone payments.
Gilead also said it is in discussions with Galapagos regarding a potential research-and-development partnership tied to these assets. As part of the arrangement, Galapagos would fund half of the upfront payment and half of any milestone obligations. It would also take on most of Ouro’s operating assets and employees. Gilead currently holds roughly a 25% stake in Galapagos and already has an agreement that provides access to its drug-discovery platform.
Gilead noted that the acquisition would strengthen its inflammation portfolio. It would add gamgertamig, which has shown efficacy after a single treatment cycle in severe antibody-mediated orphan diseases, including autoimmune hemolytic anemia and immune thrombocytopenia, in ongoing Phase 1/2 studies.
Gamgertamig has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration and is expected to move into late-stage studies in 2027, according to Gilead. The company said it plans to co-develop the asset with Galapagos, with both firms sharing trial costs. Gilead would retain most global commercialization rights and pay royalties of 20% to 23%.
Galapagos will also gain access to $500 million outside the 2019 agreement to support independent research. Gilead’s CMO, Dietmar Berger, described the move as part of the company’s effort to expand treatments for autoimmune diseases.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on developing medicines to prevent and treat serious diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation.
While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Dividend Stocks to Buy for Steady Income and Dividend Kings and Aristocrats List: 32 Biggest Stocks
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center